|
|
 Previous Article | Table of Contents | Next Article 
CD3- CD56+ non-Hodgkin's lymphomas with an aggressive behavior related to
multidrug resistance
B Drenou, T Lamy, L Amiot, O Fardel, S Caulet-Maugendre, M Sasportes, J Diebold, PY Le Prise and R Fauchet
Laboratoire d'Hematologie-Immunologie, Hopital Pontchaillou, CHRU Rennes,
France.
CD56 expression has been reported previously in some non-Hodgkin's lymphoma
(NHL) characterization. They principally involve the nasopharynx, are
related to Epstein-Barr virus (EBV), and may be classified as either T- or
non-T-natural killer (NK) cells according to CD3/T-cell receptor (TCR)
status at the genomic or protein level. The present study reports three
cases of non-nasal NK-NHL with the following characteristics: an agressive
clinical behavior, heterogenous morphological data evoking pleomorphic
T-cell malignant lymphoma, a non- T-NK phenotype using flow cytometry, and
immunochemistry. The three cases were CD56+ without membrane expression of
specific T markers (CD3, CD5, and TCR). Heterogenous results were observed
concerning different antigens: CD2, CD4, CD8, CD16, CD94, CD122, TiA1,
perforin, and granzyme B. There was no evidence of detectable clonal TCR
gene rearrangement with polymerase chain reaction. No NK activity was
detected in the two tested cases, and no relation was found with EBV.
Multidrug resistance investigations suggest that agressive clinical
findings could be related to MDR1 gene expression as confirmed by MDR1 mRNA
detection, MDR1 gene product (Pgp) expression, and a functional multidrug
resistance study using rhodamine efflux by flow-cytometry.
Volume 89,
Issue 8,
pp. 2966-2974,
04/15/1997
Copyright © 1997 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. Yamaguchi, K. Tobinai, M. Oguchi, N. Ishizuka, Y. Kobayashi, Y. Isobe, K. Ishizawa, N. Maseki, K. Itoh, N. Usui, et al.
Phase I/II Study of Concurrent Chemoradiotherapy for Localized Nasal Natural Killer/T-Cell Lymphoma: Japan Clinical Oncology Group Study JCOG0211
J. Clin. Oncol.,
November 20, 2009;
27(33):
5594 - 5600.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Assaf, S. Gellrich, S. Whittaker, A. Robson, L. Cerroni, C. Massone, H. Kerl, C. Rose, A. Chott, S. Chimenti, et al.
CD56-positive haematological neoplasms of the skin: a multicentre study of the Cutaneous Lymphoma Project Group of the European Organisation for Research and Treatment of Cancer
J. Clin. Pathol.,
September 1, 2007;
60(9):
981 - 989.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-X. Li, B. Yao, J. Jin, W.-H. Wang, Y.-P. Liu, Y.-W. Song, S.-L. Wang, X.-F. Liu, L.-Q. Zhou, X.-H. He, et al.
Radiotherapy As Primary Treatment for Stage IE and IIE Nasal Natural Killer/T-Cell Lymphoma
J. Clin. Oncol.,
January 1, 2006;
24(1):
181 - 189.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. M. Kim, Y. H. Park, S.-Y. Lee, J.-H. Kim, D.-W. Kim, S.-A. Im, T.-Y. Kim, C. W. Kim, D. S. Heo, Y.-J. Bang, et al.
Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage IE/IIE extranodal NK/T-cell lymphoma, nasal type
Blood,
December 1, 2005;
106(12):
3785 - 3790.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Feuillard, M.-C. Jacob, F. Valensi, M. Maynadie, R. Gressin, L. Chaperot, C. Arnoulet, F. Brignole-Baudouin, B. Drenou, E. Duchayne, et al.
Clinical and biologic features of CD4+CD56+ malignancies
Blood,
March 1, 2002;
99(5):
1556 - 1563.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Filipits, U. Jaeger, I. Simonitsch, C. Chizzali-Bonfadin, H. Heinzl, and R. Pirker
Clinical Relevance of the Lung Resistance Protein in Diffuse Large B-Cell Lymphomas
Clin. Cancer Res.,
September 1, 2000;
6(9):
3417 - 3423.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
M. Egashira, N. Kawamata, K. Sugimoto, T. Kaneko, and K. Oshimi
P-Glycoprotein Expression on Normal and Abnormally Expanded Natural Killer Cells and Inhibition of P-Glycoprotein Function by Cyclosporin A and Its Analogue, PSC833
Blood,
January 15, 1999;
93(2):
599 - 606.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Nicolaides, S. Dimou, and N. Pavlidis
Prognostic Factors in Aggressive Non-Hodgkin's Lymphomas
Oncologist,
June 1, 1998;
3(3):
189 - 197.
[Abstract]
[Full Text]
|
|
|
|
|
